NCT06289205View on ClinicalTrials.gov

"Comparing Methotrexate Usage Techniques to Prevent Proliferative Vitreoretinopaty After Retinal Detachment Vitrectomy"

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

May 31, 2025

Conditions

Proliferative Vitreoretinopathy

Interventions

DRUG

Methotrexate

Methotrexate will be utilised in two different ways to prevent development of proliferative vitreoretinopathy after vitrectomy for rhegmatogenous retinal detachment

Trial Locations (1)

57000

RECRUITING

Sahiwal Medical College & Teaching Hospital, Sahiwal, Pakistan, Sahiwal

All Listed Sponsors

lead

University of Health Sciences Lahore

OTHER